CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Bausch Health Companies Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Bausch Health Companies Inc
2150 St. Elzear Blvd. West
Phone: (514) 744-6792p:514 744-6792 LAVAL, QC  H7L 4A8  Canada Ticker: BHCBHC

Business Summary
Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (GI), hepatology, neurology and dermatology, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products, and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-YesYesYes-

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202412/31/2023YesYes-YesYes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board John A.Paulson 68 6/23/2022 6/14/2017
Chief Executive Officer, Director Thomas J.Appio 62 5/10/2022 4/1/2016
Chief Financial Officer, Executive Vice President Jean-JacquesCharhon 59 8/19/2024 8/19/2024
7 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
BAUSCH & LOMB SURGICAL, INC. - MISS
Bausch + Lomb Escrow Corp. Canada
Valeant Pharmaceuticals Ireland Limited 3013 Citywest Business Campus Dublin Ireland
30 additional Subsidiary records available in full report.

Business Names
Business Name
0909657 B.C. Ltd.
0919837 B.C. Ltd.
0938638 B.C. Ltd.
415 additional Business Names available in full report.

General Information
Number of Employees: 20,270 (As of 12/31/2023)
Outstanding Shares: 361,630,912 (As of 12/19/2024)
Shareholders: 1,790
Stock Exchange: TSE
Federal Tax Id: 980448205
Fax Number: (514) 744-6792


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, January 29, 2025